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ABSTRACT
Extracellular vesicles play important roles in tumor development. Many 
components of these structures, including microvesicles and exosomes, have 
been defined. However, mechanisms by which extracellular vesicles affect tumor 
progression are not fully understood. Here, we investigated vesicular communication 
between mammary carcinoma cells and neighboring nontransformed mammary 
fibroblasts. Nonbiased proteomic analysis found that over 1% of the entire proteome 
is represented in these vesicles, with the neuroblast differentiation associated protein 
AHNAK and annexin A2 being the most abundant. In particular, AHNAK was found to 
be the most prominent component of these vesicles based on peptide number, and 
appeared necessary for their formation. In addition, we report here that carcinoma 
cells produce vesicles that promote the migration of recipient fibroblasts. These 
data suggest that AHNAK enables mammary carcinoma cells to produce and release 
extracellular vesicles that cause disruption of the stroma by surrounding fibroblasts. 
This paradigm reveals fundamental mechanisms by which vesicular communication 
between carcinoma cells and stromal cells can promote cancer progression in the 
tumor microenvironment.
INTRODUCTION
Cancer kills over 8 million people every year, 
working out to a person about every 4 seconds around 
the world [1]. Breast cancer constitutes the second most 
frequent cancer worldwide. Breast cancer accounts for 
about 12% of all new cancer cases, affects about 1 in 8 
women, and is responsible for 500 thousand deaths every 
year [2, 3]. A better understanding of cancer progression is 
clearly needed to prevent and treat these cancers.
Mammary carcinoma cells interact with the 
surrounding microenvironment including extracellular 
matrix (ECM) components and normal stromal cells 
including fibroblasts [4]. Interactions between these cells 
create an environment needed to supporting tumor growth, 
invasion, and metastasis [5, 6]. These interactions can be 
mediated by direct contact by intercellular junctions or 
secreted factors that diffuse between cells independently 
or within extracellular vesicles [7].
Extracellular vesicles have recently emerged as 
important factors that regulate tumor progression in 
the microenvironment [7, 8]. These include exosomes 
that are between 30 to 100 nanometers in diameter, 
and microvesicles that are in the range of 100 to 1000 
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nanometers in diameter [9]. These vesicles transmit signals 
that regulate many aspects of cancer progression including 
angiogenesis and degradation of the extracellular matrix 
leading to tumor invasion and metastasis [7, 8, 10].
Extracellular vesicles from different cell types have 
been characterized by proteomic analysis [11, 12]. For 
example, exosomes-like vesicles from breast tumor cells 
(MDA-MB-231 and MCF-7 cells) were found to contain 
proteins including actin, annexins (A1, A2, A5), pyruvate 
kinase isoenzymes (M1/M2), tubulin (α and β), heat shock 
proteins (HSP 90α), histone (H4), and integrin α-2 [13]. 
In addition, relatively low levels of AHNAK (Neuroblast 
differentiation-associated protein; desmoyokin) and 
myoferlin proteins were found in vesicles from MCF-
7 cells [13]. The AHNAK protein was also observed in 
proteomic analysis of isolated vesicles from prostate 
tumor cells [14].
Here, we investigated the role of AHNAK in 
extracellular vesicle formation and exchange between 
mammary carcinoma cells and neighboring fibroblasts. We 
determined the number, size, composition, and potential 
function of these vesicles. Interestingly, these vesicles 
traveled with a directional tendency from aggressive 
mammary carcinoma cells to fibroblasts. Secretome 
analysis found high levels of AHNAK in vesicles from 
aggressive MDA-MB-231 cells. We also found higher 
expression of AHNAK in human breast tumor samples 
compared to normal tissue. These data indicate that 
AHNAK does not promote cell growth, but does enable 
mammary carcinoma cells to produce extracellular 
vesicles, and that these vesicles travel to, and increase 
the migration of, stromal fibroblasts. Thus, AHNAK 
appears to promote extracellular vesicle production by 
mammary carcinoma cells in order to increase fibroblast 
migration with consequent modification of the tumor 
microenvironment.
RESULTS
Mammary carcinoma cells and fibroblasts 
produce and exchange vesicles with each other
Signaling between tumor cells and stromal 
fibroblasts is crucial for development of the tumor 
microenvironment [15]. However, the role of extracellular 
vesicles in this process is not well understood. We 
utilized mammary carcinoma cells and fibroblasts from 
normal mammary tissue as a model to study this form of 
intercellular communication.
We used MDA-MB-231 and MCF-7 cells to 
represent highly aggressive and less aggressive mammary 
carcinoma cells, respectively [16]. Nontransformed 
mammary fibroblasts were expanded from primary 
cultures derived from normal human breast tissue. 
Specifically, our objective was to evaluate vesicle 
exchange dynamics between normal and tumor cells. 
Each cell type was stained with different dyes to identify 
components that transferred between tumor cells and 
nontransformed fibroblasts in co-culture. As shown in 
Figure 1a and 1b, vesicles can be seen traveling between 
mammary carcinoma cells and fibroblasts. This vesicular 
transfer is confirmed by orthogonal projections from 
confocal optical sections. Quantitation of these data 
found that vesicles traveled more frequently from tumor 
cells to fibroblasts than from fibroblasts to tumor cells, as 
shown in Figure 1c. In addition, about 4 times as many 
vesicles traveled to fibroblasts from MDA-MB-231 cells 
than from MCF-7 cells. Thus, more aggressive MDA-
MB-231 carcinoma cells transferred more vesicles than 
less aggressive MCF-7 cells.
Vesicles and cell membrane protrusions can be 
visualized by electron microscopy
Electron microscopy was used to analyze the 
morphology of vesicles produced by mammary carcinoma 
cells and fibroblasts used in this study. Transmission 
electron microscopy (TEM) revealed cell protrusions 
that appeared to produce microvesicles (indicated by 
arrowheads in Figure 2a-2c). In general, more protrusions 
were found in carcinoma cells than in nontransformed 
fibroblasts.
In addition to cell protrusions, vesicular structures 
were also found inside and outside of cells. Most 
extracellular vesicles had diameters ranging from 200 to 
400 nm (Figures 2a-2c). However vesicles isolated from 
conditioned medium were observed with different electron 
densities and diameters ranging from 200 to 700 nm as 
shown in Figure 2d.
Scanning electron microscopy (SEM) was utilized 
to further examine the morphology of cell protrusions seen 
by TEM. These images, shown in Figures 2e-2h confirm 
the potential of cells to form vesicular structures between 
200 to 700 nm in diameter. These were particularly 
prominent in MDA-MB-231 cells (Figure 2h). In general, 
these data highlight the production of extracellular vesicles 
compatible in size and shape with microvesicles over 100 
nm in diameter.
Extracellular vesicle size examined by 
nanoparticle tracking analysis (NTA)
NTA analysis was used to examine the number 
and size of vesicles released into media by fibroblasts, 
MCF-7 cells, and MDA-MB-231 cells. As shown in 
Figure 3a, MDA-MB-231 cells produced the most 
extracellular vesicles, followed by less aggressive 
MCF-7 cells, and nontransformed fibroblasts. These 
data confirmed results obtained by electron microscopy. 
However, NTA analysis detected more vesicles 
smaller than 120 nm in diameter than seen by electron 
microscopy. This is consistent with the ability of 
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Figure 1: Mammary carcinoma cells exchange vesicles with nontransformed mammary fibroblasts. Panels a. and b. 
present confocal images showing exchange of vesicular structures between fibroblasts (green) and tumor cells (red, arrows in panels a 
and b). Orthogonal projections verify the presence of tumor vesicles inside fibroblasts (arrowheads in panels a and b). Panel c. presents 
quantitation of vesicle transfer as numbers of vesicles transferred in a field containing 20 cells (mean+SEM, n≥5). Single, double, and triple 
asterisks indicate statistically significant differences of p<0.05, p<0.01 and p<0.001, respectively. Scale bars = 20 μm.
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Figure 2: Vesicular structure characterization by electron microscopy. Transmission electron microscopy analysis of 
a. fibroblasts, b. MCF-7 cells, and c.MDA-MB-231 cells are shown with vesicular structures with size ranging from 200-400 nm indicated 
by arrows. TEM also found membrane protrusions, mostly in MDA-MB-231 cells as indicated by arrowheads in panel c. d. Vesicles 
isolated from MDA-MB-231 cells consisted of a heterogeneous population with different diameters and electron-densities. Scanning 
electron microscopy images of e. fibroblasts, f. MCF-7 cells, and g-h. MDA-MB-231 cells display cell protrusions indicated by arrowheads 
and vesicles indicated by arrows, particularly on MDA-MB-231 cells. Average vesicles size is approximately 200 nm in diameter. Scale 
bars for A-C = 200 nm, D = 500 nm, E-G = 10 μm, and E = 1 μm.
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Figure 3: Nanoparticle tracking and LC-MS/MS analysis of extracellular vesicles. a. NTA images of vesicles isolated from 
MDA-MB-231 cells, MCF-7 cells, and fibroblasts as indicated. Vesicles were quantitated into sizes between 10-120 nm and 120-690 
nm by NanoSight technology. Results are shown as the number of vesicles within each size range (mean+SEM, n=3). Single and double 
asterisks indicate statistically significant differences of p<0.05 and p<0.01, respectively. Scale bar = 5 μm. b. Selected proteins identified 
in vesicles from MDA-MB-231 cells by trypsin digestion and LC-MS/MS analysis are shown along with their peptide number and relative 
abundance color coded from green to red, as indicated. c. AHNAK and β-actin protein levels in nontransformed fibroblasts, MCF-7 cells, 
MDA-MB-231 cells, and in isolated vesicles from MDA-MB-231 cells were examined by Western blotting. Vesicles derived from MDA-
MB-231 cells were enriched with AHNAK. d. Protein from exosomes (Exo), microvesicles (MV), whole cell lysates (WCL), and whole 
cells lysates from MDA-MB-231 cells treated with 1 μM staurosporine for 24 hours (WCL+Stau) to induce apoptosis were examined by 
Western blotting for AHNAK, flotillin, TSG101, β-actin, Bax, and cleaved caspase 3 as indicated. Microvesicles contained AHNAK but 
not apoptotic markers (cleaved caspase-3 and BAX). Exosomes were enriched with Flotillin and TSG101, but not AHNAK nor apoptotic 
markers.
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NanoSight technology to detect smaller vesicles more 
efficiently than electron microscopy [17, 18].
Extracellular vesicle composition defined by 
proteomic analysis and immunoblotting
Mass spectrometry (LC-MS/MS) identified 
over 270 proteins in extracellular vesicles produced 
by MDA-MB- 231 cells (see Supplementary Table 
S1). These data indicate that at over 1% of the entire 
proteome may be represented in extracellular vesicles 
from mammary carcinoma cells. While many of these 
proteins have been previously identified in extracellular 
vesicles, some may have not yet been reported. The most 
abundant vesicular proteins included AHNAK, annexin 
A2 (ANXA2), filamin A (FLNA), and three heat shock 
proteins including 78 kD glucose-related protein (HSPA5), 
HSP90 alpha (HSP90AA1), and HSP90 beta (HSP90B1) 
(Supplementary Table S1).
In particular, AHNAK was identified as the most 
prominent vesicle protein, along with several of its 
binding partners including annexin A2, annexin A6, 
myoferlin, and protein S-100 as shown in Figure 3b. As 
vesicles were mostly enriched with AHNAK, we sought 
to further validate this finding by immunoblot analysis. 
We confirmed that AHNAK is significantly expressed 
in extracellular vesicles as well as in the cell lines 
investigated as shown in Figure 3c.
Our next objective was to better characterize the 
vesicles isolated. Specifically, we wanted to address the 
possibility of contamination of extracellular vesicles with 
apoptotic bodies. We observed that these vesicles did not 
contain well known markers of apoptosis (i.e., BAX and 
cleaved caspase 3). In contrast, these apoptotic markers 
were found in positive controls (i.e. MDA-MB-231 
staurosporine-treated lysate) as shown in Figure 3d.
We next determined whether exosomes also express 
AHNAK. Isolation of exosomes was successful, as 
demonstrated by enrichment with exosome markers (i.e. 
Flottilin-1, TSG-101). Interestingly, AHNAK was not 
detected in the exosomes, which points to microvesicles 
as the main source of AHNAK among the extracellular 
vesicles (Figure 3d).
AHNAK localizes to cell membranes and vesicles
Confocal microscopy was used to examine the 
expression of AHNAK in mammary carcinoma cells and 
vesicles. As shown in Figure 4a, AHNAK was concentrated 
along the lateral plasma membrane, with more diffuse 
expression throughout the cytoplasm of MDA-MB-231 
cells. AHNAK was also particularly concentrated at 
regions of intercellular contacts in MCF-7 cells (arrowhead 
in Figure 4b). In addition to these cell membrane and 
diffuse cytoplasmic locations, AHNAK showed punctate 
expression in vesicles (arrows in Figure 4a-4c).
In order to further confirm the subcellular 
localization of AHNAK, we performed immunogold 
labeling of MDA-MB-231 cells and observed AHNAK 
presence at cell plasma membrane and vesicle-like 
structures (Figure 5). Our ultrastructural analysis revealed 
a staining pattern similar to that previously found for small 
vesicles termed enlargeosomes in neuronal cells [19].
Cells were co-cultured to examine AHNAK in 
vesicles that transferred from mammary carcinoma cells to 
neighboring fibroblasts. As shown in Figure 6a, AHNAK 
was present in vesicles produced by MDA-MB-231 cells 
that traveled to fibroblasts. This is particularly clear in 
merged images (arrow in Figure 6a) and orthogonal 
projections showing well defined vesicles inside 
fibroblasts as shown in Figure 6b. The graphic in Figure 
6c shows an overlap between MDA-MB-231 vesicle (red 
channel) and AHNAK (blue channel). We, therefore, 
sought to investigate the role of AHNAK in mammary 
carcinoma extracellular vesicles.
AHNAK is required for vesicle production and 
exchange
The role of AHNAK in vesicle production and 
exchange was further explored by siRNA-mediated 
depletion of protein expression. Results from 
immunofluorescence microscopy and western blotting 
indicated that AHNAK production was efficiently targeted 
by this method in MDA-MB-231 cells (Figure 7a). We 
also found that AHNAK did not affect cell proliferation 
or viability of these cells (Supplementary Figure S1), 
indicating that AHNAK expression was not critical for 
mammary carcinoma cell growth.
These data were confirmed by nanoparticle tracking 
analysis. As shown in Figure 7b, AHNAK depletion 
decreased the number and size of vesicles present in 
conditioned medium of MDA-MB-231 cells compared 
to control cells. Interestingly, this effect seemed specific 
for larger vesicles. While the production of smaller 
vesicles with diameters of 10 to 120 nm (consistent 
with exosomes) was not significantly affected, AHNAK 
knockdown decreased the production of larger vesicles 
with diameters of 120 to 750 nm in diameter (consistent 
with microvesicles) by about 2 fold. Results from MDA-
MB-231 cells cultured with nontransformed fibroblasts 
indicated that AHNAK knockdown caused a proportional 
decrease in the exchange of vesicles between these two 
cell types. As shown in Figure 7c, MDA-MB-231 cells 
transfected with AHNAK siRNA transferred about 2 fold 
less vesicles to fibroblasts than control cells.
The effects of AHNAK depletion on the formation 
of cell membrane protrusions and extracellular vesicles 
were also examined by electron microscopy. TEM analysis 
revealed that MDA-MB-231 cells transfected with 
AHNAK siRNA formed less cell protrusions than controls 
as shown in Figure 8a-8b. SEM analysis also found that 
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Figure 4: AHNAK localization in cell protrusions and extracellular vesicles. AHNAK was visualized in cells by 
immunofluorescence confocal microscopy. a. MDA-MB-231 cells contained AHNAK at cell edges, as dot-like structures in the lamellipodia 
(insert), and in released vesicles (arrow). b. MCF-7 cells contained AHNAK mostly at intercellular junctions (arrowheads) and vesicles 
(arrows). c. Nontransformed fibroblasts contained AHNAK at cell edges and as small dots throughout the cytoplasm. Scale bars = 5 μm.
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AHNAK depletion decreased the number of vesicles 
produced by MDA-MB-231 cells compared to controls as 
shown in Figure 8c-8f. Quantitation of these data shown in 
Figure 8g-h indicates that AHNAK depletion significantly 
reduced the formation of protrusions and vesicles by over 
2 fold and 5 fold, respectively. Results from electron 
microscopy indicated that AHNAK plays a functional 
role in the formation of cell protrusions and extracellular 
vesicles.
AHNAK expression is increased in human breast 
tumors
Taken together, results from electron microscopy 
and nanoparticle tracking analysis suggest that AHNAK 
is needed for mammary carcinoma cells to produce 
microvesicles. Results from these in vitro experiments 
prompted us to compare the expression patterns of 
AHNAK in human clinical samples. AHNAK expression 
in normal mammary epithelium, invasive ductal 
carcinoma, and metastatic carcinoma were examined 
by immunohistochemistry as shown in Figure 9. Weak 
AHNAK staining was found in relatively few normal 
cells (Figure 9a). In contrast to normal cells, robust 
AHNAK expression was seen in the cytoplasm and plasma 
membrane of the majority of invasive ductal carcinoma 
cells (Figure 9b). Metastatic carcinoma cells contained 
the highest levels of AHNAK expression, particularly 
at the plasma membrane (Figure 9c). AHNAK staining 
seemed specific for carcinoma cells and was not prominent 
in stroma. Quantitation of these data indicates that 
AHNAK expression was significantly higher in mammary 
carcinoma cells than normal epithelium (Figure 9e).
Extracellular vesicles from MDA-MB-231 cells 
promote fibroblast cell migration
Results from imaging, mass spectroscopy, and 
siRNA experiments indicate that AHNAK supports 
the ability of mammary carcinoma cells to produce 
extracellular vesicles that enter neighboring fibroblasts. 
Fibroblasts can play important roles in promoting cancer 
progression in the tumor microenvironment [15, 20–
22]. Increased migration is a hallmark of these cancer 
associated fibroblasts (CAFs). As shown in Figure 10a, 
nontransformed fibroblasts treated with vesicles from 
MDA-MB-231 cells migrated over 30% more than cells 
without vesicles. In contrast to cell migration, these 
vesicles did not increase fibroblast cell proliferation (data 
not shown). These data indicate that extracellular vesicles 
from mammary carcinoma cells can increase the motility 
of recipient mammary fibroblasts.
DISCUSSION
Cancer development is driven by interactions 
between tumor cells and their surrounding stroma [6]. 
The tumor stroma is composed of an extracellular 
matrix and a variety of cells including fibroblasts, which 
can affect cancer progression [6, 23]. Emerging data 
Figure 5: Subcellular localization of AHNAK in MDA-MB-231 cells. a. TEM microscopy magnification shows general 
distribution of AHNAK. b. Higher magnification of the inset field finds that AHNAK was detected at vesicle-like structures (arrowheads) 
and near the plasma membrane or cell protrusions (arrows).
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Figure 6: AHNAK localization in vesicles transferred from MDA-MB-231 cells to nontransformed fibroblasts. a. MDA-
MB-231 cells and fibroblasts were stained red and green, respectively, and cultured together for 48 hours before AHNAK was detected by 
immunofluorescence (blue). AHNAK can be seen in vesicles, including vesicles in fibroblasts that were produced by MDA-MB-231 cells 
(indicated by arrow). b. Volume rendering of confocal images to create an orthogonal plot showing a magenta vesicle derived from MDA-
MB-231 cells and containing AHNAK inside a nontransformed fibroblast (indicated by arrow). Scale bar = 5 μm. c. Linescan profiles from 
the region indicate by arrow in (b) display a clear overlap between AHNAK (blue) and MDA-MB-231 vesicles (red).
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Figure 7: AHNAK depletion impairs microvesicle formation and exchange. a. siRNA was used to deplete AHNAK expression 
in MDA-MB-231 cells, as observed by immunofluorescence (left panel) and immunoblot analysis (right panel). b. Cells with reduced 
AHNAK expression showed a significant decrease in microvesicle formation compared to controls. c. Depletion of AHNAK decreased 
vesicle transfer from MDA-MB-231 cells to fibroblasts. Data are shown as vesicles transferred between different cell types (mean+SEM, 
n=3). Single and double asterisks indicate statistically significant differences of p<0.05 and p<0.01, respectively.
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Figure 8: AHNAK downregulation abrogates formation of cell protrusions and extracellular vesicles. MDA-MB-231 
cells were transfected with scrambled or AHNAK siRNA and examined by electron microscopy as indicated. a-b. TEM analysis with cell 
protrusions indicated by arrows. c-d. SEM analysis of MDA-MB-231 cell surfaces. e-f. magnified regions outlined in panels C and D with 
examples of protrusions and vesicles indicated by arrows and arrowheads, respectively. Number of g. protrusions and h. vesicles per cell 
were quantitated and shown as protrusions or vesicles per cell (mean+SEM, n=20 in at least three different experiments). Double and triple 
asterisks indicate significant differences with p<0.01 and p<0.001 compared to control cells transfected with scrambled siRNA. Scale bars 
in A-B = 500 nm, C-D = 1 μm, and E-F = 10 μm.
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Figure 9: AHNAK is highly expressed in human mammary carcinoma cells in vivo. AHNAK expression was evaluated in 
human clinical samples by immunohistochemistry. a. normal mammary epithelium, b. invasive ductal carcinoma, c. metastatic carcinoma 
from breast cancer patients, and d. invasive ductal carcinoma without primary antibody as a negative control. e. Quantitation of these data 
is shown as the percent of area with AHNAK expression (mean±SEM), and indicate that AHNAK expression was increased in invasive 
ductal carcinoma (n=35) and metastatic carcinoma (n=10) compared to normal tissue (n=9). Triple asterisks indicate significant differences 
compared to normal tissue with p<0.001. Scale bar = 20 μm.
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indicate that critical interactions between tumor cells and 
their surrounding stroma are mediated by exchanges of 
extracellular vesicles [7]. In this study, we demonstrated 
the presence and exchange of vesicles between human 
mammary carcinoma cells and nontransformed fibroblasts 
from breast tissue. This communication was directional, 
with tumor cells producing more vesicles than the 
fibroblasts. Thus, net movement from tumor cells to 
fibroblasts may result from simple dynamics as opposed 
to molecular targeting.
Results from this study found vesicular structures 
ranging from 500 nm to 1 μm in diameter. Vesicles 
presenting size greater than 100 nm may originate 
by sprouting from the plasma membrane [8]. Thus, 
vesicles isolated and characterized in this study may 
be classified as microvesicles shed from the plasma 
membrane, as opposed to exosomes produced by 
exocytosis of multivesicular bodies and granules [7, 
24, 25]. These data are consistent with production of 
microvesicles and exosomes by breast cancer cells 
reported by others [25, 26].
Our nonbiased analysis of extracellular vesicles 
produced by mammary carcinoma cells found AHNAK 
as the most prominent component. We confirmed the 
presence of AHNAK in isolated vesicles and cells by 
immunofluorescence and immunoblot analysis. AHNAK 
is a large protein of approximately 700 kDa found at the 
inner plasma membrane [27] in different cell types [28].
AHNAK participates in the formation of 
enlargeosomes, which are cytoplasmic vesicles first 
observed in neuronal cell lines [29]. Annexin-A2, 
which we found to be abundant in MDA-MB-231-
derived vesicles, was also demonstrated to be present in 
enlargeosomes and to be necessary for its exocytosis [30]. 
Functionally, enlargeosomes can participate in processes 
including cell differentiation and membrane repair [29, 
31]. Relatively low levels of AHNAK and myoferlin 
proteins have been found in vesicles produced by MCF-7 
cells [13]. AHNAK has also been found in vesicles from 
primary human myotubes [32]. However, the functional 
relevance of AHNAK in mammary carcinoma derived 
vesicles has not been elucidated. Results from this study 
indicate that AHNAK is needed for vesicle production, 
and that these vesicles might augment tumor progression 
by mobilizing CAFs. These findings are consistent with 
reports of increased AHNAK expression in melanoma [33] 
and laryngeal cancer [34].
We found that depletion of AHNAK by siRNA 
did not affect mammary carcinoma cell growth in 
vitro, but inhibited the ability of these cells to produce 
microvesicles. This finding is consistent with the results 
of Shankar et al who demonstrated that AHNAK siRNA 
Figure 10: Extracellular vesicles derived from MDA-MB-231 cells promote fibroblast cell migration. Nontransformed 
fibroblasts were plated on membrane with 8-micron pores in Transwell inserts with or without vesicles isolated from MDA-MB-231 cells 
as indicated, cultured in serum-free medium for 24 hours, and fixed with PFA. Cells on the upper side of the membranes were removed, and 
migrated cells on the lower side were stained with crystal violet, photographed, and counted. Cell motility was quantitated as the number 
of cells that migrated from the top of the membrane to the bottom of the membrane (mean+SEM, n=5). Double and triple asterisks indicate 
significant differences with p<0.01 and p<0.001, respectively, as indicated.
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knockdown did not affect MDA-MB-231 cell viability, 
but resulted in pseudopod retraction, reduced actin 
cytoskeleton dynamics, reversion of EMT, and inhibition 
of cell migration and invasion [35]. Also, AHNAK-
deficient mice are viable and present no developmental 
defects [36]. Taken together, our results indicate that 
AHNAK enables mammary carcinoma cells to form and 
release extracellular vesicles that travel into recipient 
fibroblasts.
It is becoming increasingly clear that CAFs remodel 
the tumor microenvironment to promote the invasion of 
neighboring carcinoma cells. This has been demonstrated 
in different types of squamous and glandular carcinomas 
[15, 20–22]. However, mechanisms that convert normal 
fibroblasts to tumor promoting CAFs have not been 
elucidated. Here, we found that mammary carcinoma cells 
produce vesicles that may play a role in this process.
Our data demonstrate that extracellular vesicles 
produced by tumor cells can increase motility of 
neighboring fibroblasts. However, concentrations 
of factors including serum, growth factors, and 
extracellular vesicles are likely to vary in the actual tumor 
microenvironment. Thus, the effects of extracellular 
vesicles on cell motility would be highly dependent on 
specific conditions in vivo. Nonetheless, pathways forged 
by these fibroblasts can be followed by carcinoma cells in 
the tumor microenvironment to augment tumor invasion 
and metastasis [20–22]. This scenario is supported 
by our finding that AHNAK production is elevated in 
invasive and metastatic human breast cancer cases. Thus, 
this process presents AHNAK, and potentially other 
components of extracellular vesicles, as new functionally 
relevant biomarkers and chemotherapeutic targets that 
can be used to detect and inhibit extracellular vesicles 
formation and tumorigenic intercellular communication.
MATERIALS AND METHODS
Cell lines and experimental culture conditions
MCF-7 and MDA-MB-231 mammary carcinoma 
cells were cultured in Dulbecco’s modified Eagle’s 
Medium-F12 (Sigma Chemical Co., St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (Gibco, Life 
Technologies, Eugene, Oregon, USA). Alternatively, 
MDA-MB-231 treated for 24h with 1μM Staurosporine 
served as a positive control for apoptosis. Nontransformed 
mammary fibroblasts were expanded from primary cultures 
derived from normal human breast tissue obtained from 
esthetic mammoplasty of a 22 year-old patient (Approved 
by Institutional Ethics Committee). These fibroblasts 
were maintained in DMEM (Sigma) supplemented 
with 10% FBS, 10 μg/ml ascorbic acid (Sigma), 5 U/ml 
penicillin solution and 5 μg/ml streptomycin (Gibco, Life 
Technologies). Cells were maintained in 75 cm2 flasks in a 
humidified atmosphere of 5% CO2 at 37°C.
Co-culture
Nontransformed mammary fibroblasts were co-
cultured with mammary carcinoma cells to analyze 
interactions between these cells. Briefly, fibroblasts 
were cultured over glass coverslips until reaching 90% 
confluence. Fibroblasts were loaded with green dye 
(Cell Tracker Green CMFDA, AM, Life Technologies). 
Mammary tumor cells, previously loaded with red dye 
(Cell Tracker Orange CMRA-AM, Life Technologies) 
were then plated over fibroblast monolayers. After 
tumor cell adhesion (24 hours), medium was removed 
and replaced with serum-free medium. After 24 hours, 
cells were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) and coverslips were mounted 
with SlowFade Gold Antifade Reagent with DAPI (Life 
Technologies). Cells were analyzed with a Zeiss LSM 
780 NLO confocal microscope (CEFAP-ICB), controlled 
by ZEN 2011 software. Special attention was devoted 
to interactions between the two lineages, represented 
by membrane events such as presence and exchange of 
vesicles.
Isolation of extracellular vesicles from MDA-
MB-231 cells
MDA-MB-231 cells (107) were cultured in 150 
cm2 flasks until 90% confluent, washed and cultured in 
serum-free medium for 24 hours. Conditioned media 
was removed, filtered through 0.8 μm pore membranes 
(Corning, NY, USA) to remove non-viable cells and 
debris, and centrifuged at 15.000 × g for 30 minutes at 4°C 
as previously described [37]. In order to further isolate 
exosomes, supernatant from the previous centrifugation 
was ultracentrifuged at 80,0000g for 3h at 4°C.
Transmission electron microscopy (TEM) 
analysis
Cells were grown to 90% confluence before being 
washed and cultured in serum-free medium for 24 hours. 
Cells were then scraped off, pelleted, fixed in 2.5% 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 
7.2) overnight, and postfixed in 1% osmium tetroxide in 
the same buffer for 2 hours. Samples were then washed in 
distilled water, stained in bloc with 0.5% uranyl acetate, 
rinsed and dehydrated in graded ethanol. After immersion 
in propylene oxide, samples were embedded in epoxy 
resin (Spurr, Electron Microscopy Sciences, EMS, 
Hatfield PA, USA) and polymerized for 42 hours at 75°C. 
Sections (0.5 μm-thick) were stained with 1.0% toluidine 
blue in 1.0% aqueous sodium borate for light microscopic 
examination. Ultrathin sections were stained with lead 
citrate and uranyl acetate and examined in a JEOL 1010 
transmission electron microscope (Jeol Inc., Peabody, MA, 
USA) at 80 kV.
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Extracellular vesicles were obtained and pelleted by 
centrifugation as described above, suspended in PBS, and 
5 μl of samples were deposited on carbon coated copper 
grids (CF100-Cu, EMS), incubated at room temperature 
overnight, and fixed with 2.5% glutaraldehyde for 5 
minutes. Grids were washed with distilled water several 
times and stained with 1% uranyl acetate for 5 minutes, 
followed by TEM analysis.
Scanning electron microscopy (SEM) analysis
Cells were plated and grown on coverslips for 24 
hours, fixed with 2% glutaraldehyde in 0.1 M sodium 
cacodylate buffer (pH 7.2) for 2 hours, washed with PBS, 
and postfixed in 1% osmium tetroxide in the same buffer 
for 1 hour. The cells were then dehydrated in a series of 
increasing ethanol concentrations, dried in a critical point 
apparatus (Bal-Tec CPD-030 Critical Point Dryer, Bal Tec, 
Liechtenstein), and sputter-coated with gold (SCD-040, 
Bal Tec, Liechtenstein). Cells were examined in a JEOL 
JSM-7401F scanning electron microscope (SEM - JEOL 
JSM-7401F FESEM, Tokyo, Japan) at 5.0 kV.
Extracellular vesicles analysis and quantification 
by nanoparticle tracking analysis (NTA)
Extracellular vesicles obtained from conditioned 
media were obtained as described above and suspended in 
sterile PBS. Extracellular vesicles number and size were 
counted with nanoparticle tracking analysis equipament 
(NanoSight LM10, Amesbury, UK), equipped with a 
charge-coupled device (CCD) camera and a laser emitting 
a 60-mW beam at 405 nm wavelength. Acquisitions 
were performed in five records of 60 seconds using the 
following parameters: shutter of 604, gain of 100, and 
threshold of 10. At least 1,000 particles were tracked 
in each sample. Brownian motion of particles was used 
to calculate particle size and concentration by NTA 3.0 
software (NanoSight).
Mass spectrometric analysis
Protein from extracellular vesicles isolated from 
MDA-MB-231 cells was subjected to tryptic digestion. 
Briefly, protein was incubated in 4M GuHCl and 5mM 
DTT at 65°C for 60 minutes. Iodoacetamide was then 
added to a final concentration of 15 mM and the samples 
were incubated for 60 minutes at room temperature. 
DTT was then added to a final concentration of 15 mM 
to quench excess Iodoacetamide. Digested protein was 
precipitated with 8 volumes of acetone and 1 volume 
methanol for 3 hours at −80°C, centrifuged 10.000 × g for 
10 minutes, washed twice with methanol, and suspended 
in 2.5 mM NaOH followed by 50 mM HEPES buffer, 
pH 7.5 to a final volume of 100 μL. Trypsin (Proteomics 
grade; Sigma, St. Louis, MO, USA) was added at 1:100 
ratio (enzyme/substrate), and protein samples were 
incubated at 37°C for 18 hours.
Tryptic peptides were desalted with Sep-Pak 
Vac C18 1cc (Waters, Milford, USA), vaccum dried, 
suspended in 10 μL of 0.1% formic acid. The peptide 
mixture was injected into a trap column (100 μm i.d. × 2 
cm) packed with AQUA C18, 5 μm beads (Phenomenex), 
and then separated on a 10-cm long fused silica emitter 
packed with 1.9 μm-diameter Reprosil-Pur C-18-AQ 
beads. Nanoflow liquid chromatography was performed 
at a flow rate of 400 nL/min, on a Proxeon Easy nanoLC 
HPLC (Thermo Fisher Scientific, California, USA) 
coupled to an LTQ-Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific). Peptides were loaded onto the 
column with buffer A (0.1% acetic acid) and eluted with 
a 150 minutes gradient from 0 to 80% B (acetonitrile in 
0.1% formic acid). The mass spectrometer was operated 
in data dependent mode, in which one full MS scan was 
acquired in the m/z range of 300-1650 followed by MS/
MS acquisition using collision induced dissociation 
of the ten most intense ions from the MS scan. MS 
spectra were acquired in the Orbitrap analyzer at 30,000 
resolution (at 400 m/z) and MS/MS scans were acquired 
in the linear ion trap. Dynamic exclusion was defined 
by a list size of 500 features and exclusion duration of 
90 seconds. A target value of 1,000,000 was set for the 
survey (MS) scan, and the target value for the fragment 
ion (MS/MS) spectra was set to 40,000 ions. The lower 
threshold for targeting precursor ions in the MS scans 
was 5,000 counts.
Mass spectrometric (RAW) data were analyzed with 
MaxQuant software (version 1.5.0.1.2. A False Discovery 
Rate (FDR) of 1% was required for both protein and 
peptide identifications. The MS/MS spectra were searched 
against the UniProt database, restricted to Homo sapiens 
taxonomy. Enzyme specificity was set to trypsin and 
at least two missed cleavages were allowed; cysteine 
carbamidomethylation was selected as fixed modification 
whereas methionine oxidation and glutamine/asparagine 
deamidation were selected as variable modifications. 
Peptide identification was based on a search with an 
initial mass deviation of the precursor ion of 7 ppm and 
the fragment mass tolerance was set to 20 ppm.
Depletion of AHNAK by siRNA
Cells were transfected with siRNA specific for 
AHNAK (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA), according to the manufacturer’s instructions. 
Briefly, cells were incubated with a complex formed by 
the siRNA (10 μM), transfection reagent (Lipofectamine 
2000, Life Technologies), and transfection medium (Opti-
MEM I, Gibco, Life Technologies) for 48 hours at 37°C. 
Scrambled siRNA was used as a negative control. Cell 




Cells were lysed with RIPA buffer (150 mM NaCl, 
1.0% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM 
Tris pH 8.0) containing protease inhibitors (Sigma). 
After centrifugation (10,000 × g) for 10 minutes at 4°C, 
supernatants were recovered and quantified (BCA kit, 
Pierce Inc Rockford, IL, USA). Samples were suspended 
in Laemmli buffer containing 62.5 mM Tris–HCl (pH 
6.8), 2% sodium dodecyl sulphate (SDS), 10% glycerol, 
5% mercaptoethanol and 0.001% bromophenol blue. 
Equal amounts of protein (20 μg) from cell lysates 
and extracellular vesicles were electrophoresed on 
6% polyacrylamide gels, transferred to Hybond ECL 
nitrocellulose membranes (Amersham), and blocked in 
Tris-buffered saline (TBS 1X) with 5% non-fat milk for 1 
hour or TBS 1X with 0.05% Tween 20 (TBST), overnight 
at 4°C. Following one wash in TBST, membranes were 
probed with antibodies against AHNAK (1:1000, H-153, 
sc-98373, Santa Cruz Biotechnology) and β-actin 
(1:2000, Sigma), followed by appropriate secondary 
antibodies which were detected by chemiluminescence 
(ECL).
Immunofluorescence
Cells were fixed with 4% PFA in PBS and 
permeabilized with 0.5% Triton X-100 (Sigma) in PBS 
for 5 minutes. Samples were then blocked with 10% 
normal goat serum (KPL, Gaithersburg, USA) for 1 hour, 
and incubated with primary antibody against AHNAK 
(mouse monoclonal clone E5; Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA) diluted 1:50 in PBS for 1 hour 
at room temperature. Primary antibody was detected by 
goat anti-mouse secondary antibodies, conjugated to either 
Alexa Fluor 568 or Alexa Fluor 647 (Life Technologies, 
Eugene, Oregon, USA) for 1 hour protected from light. 
Samples were mounted in ProLong with DAPI to stain 
nuclei (Life Technologies). Non-immune serum served as 
negative controls.
Results were analyzed by fluorescence microscopy 
(Axiophot, Carl Zeiss, Oberkochen, Germany) using a 
PlanApo 100x objective (1.45NA). Cell images were 
acquired with a digital CCD monochromatic camera 
(CoolSnap HQ2, Photometrics Inc, Tucson, AZ, USA). 
The microscope and additional hardware were controlled 
by Metamorph Premier 7.6 software (Molecular Devices, 
Sunnyvale, CA, USA). Samples were also analyzed 
by confocal microscopy with a Leica TCS AOBS SP8 
Tandem Scanner with spectral detection system Leica SP 
Detector (Leica Microsystems, Germany). Measurements 
of colocalization areas were determined using ImageJ 
public domain software (http://rsb.info.nih.gov/ij/). 
Colocalization analysis was carried out by the Linescan 
tool (Metamorph Premier 7.6 software), and the Image 
J plugin JaCop (http://rsb.info.nih.gov/ij/plugins/track/
jacop.html).
Immunogold electron microscopy
Cell pellets were fixed with 0.1% glutaraldehyde 
and 4% PFA in PBS for 1 hour. Fixative was removed 
by centrifugation and cells were washed twice in 0.05M 
glycine in PBS. After one wash in PBS, cells were 
permeabilized and blocked in 0.1% saponin and 5% goat 
serum for 30 min. Samples were then incubated with 
primary antibody against AHNAK (mouse monoclonal 
clone E5; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA) diluted 1:50 in 10% goat serum for 1 hour 
at room temperature. Primary antibody was detected by 
anti-mouse secondary antibody, conjugated to Nanogold 
1.4nm (Nanogold, Yaphank, NY, USA) diluted 1:50 in 
10% goat serum for 1 hour. Gold Enhance EM Plus was 
used according to manufacturer’s instructions to enlarged 
gold particle size. Non-immune serum served as negative 
controls. Results were analyzed in a FEI Tecnai G20 
Electron microscope at 200kVA.
Cell proliferation assay
Cells were incubated for 24 hours with 60 μM BrdU 
(Sigma Chemical Co, St. Louis, MO, USA) in serum-free 
medium, fixed, and DNA was denatured in 2 N HCl for 30 
minutes, then neutralized in 0.1 M borate buffer (0.1 M 
H3BO3, 0.15 M NaOH, pH 8.4) for 10 minutes. Cells were 
incubated with 0.3% Triton X-100 in PBS for 15 minutes 
and blocked with 1% bovine serum albumin (BSA, 
Sigma) and 0.1% Triton X-100 in PBS for 1 hour. Cells 
were then incubated with anti-BrdU biotinilated primary 
antibody (Biotin mouse, 1:100, MAB 3262B, Millipore) 
overnight, washed, and incubated with Alexa Fluor 555 
streptavidin (1:500, Life Technologies, Eugene, Oregon, 
USA) secondary antibody for 1 hour. Cells were washed 
and nuclei stained with DAPI.
Images were taken from at least four fields by 
fluorescence microscopy (Axio vert A1, Carl Zeiss, 
Germany) using a LD-Plan 20x objective. Images were 
acquired with a digital AxioCam MRc camera (Carl Zeiss, 
Germany), and analyzed by ImageJ software to calculate 
the percentage of BrdU-positive nuclei from total nuclei 
number.
Immunohistochemistry
Tissue microarray slides from normal human and 
breast cancer samples were obtained from Imgenex (San 
Diego, CA; IMH-364). Sections (4μm) from 54 samples 
were analyzed, including 35 cases of invasive ductal 
carcinoma (IDC), 10 cases of cancer metastasis, and 9 
samples of normal breast tissue adjacent to cancer tissue.
Sections were deparaffinized in xylene and hydrated 
in decreasing ethanol concentrations. Antigen retrieval 
was carried out with citrate buffer (10 mM citric acid, 
0.05% Tween 20, pH 6.0) in a water bath (95-100°C) for 
30 minutes. Sections were blocked for 1 hour with 1% 
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BSA (Sigma) in PBS. AHNAK was identified with a rabbit 
polyclonal antibody (1:100 in PBS, HPA026643, Sigma) 
overnight at 4°C. Endogenous peroxidase blocking was 
performed for 20 minutes, followed by Biotin-conjugated 
anti- rabbit secondary antibody (Dako) for 30 minutes. 
Diaminobenzidine (Sigma) was used as chromogen, and 
sections were counterstained with Mayer’s hematoxylin 
(Sigma).
Brightfield images from five randomly selected 
fields from each sample were acquired with a Primostar 
microscope (Carl Zeiss, Germany) equipped with a CCD 
color camera (AxiocCam HRc, Carl Zeiss). All images 
were acquired at the same magnification (40x). Areas of 
diaminobenzidine staining were segmented using the color 
deconvolution plug-in of ImageJ (public domain software 
developed by Wayne Rasband, NIMH, NIH, Bethesda, 
MD, USA, http://rsbweb.nih.gov/ij/) to segment images 
and calculate the percent of AHNAK positive area.
Cell migration assay
Migration assays were carried out in Transwell inserts 
with 8 μm pores in 12 well plates (Corning). Fibroblasts 
(5 × 104) were plated into upper chambers in serum-free 
medium. Lower chamber were filled with vesicles derived 
from MDA-MB-231 cells (100μg/ml), diluted in serum-free 
medium. Complete media and serum-free media were also 
used as controls. Cells were cultured in these conditions for 
24 hours before inserts were fixed with 4% PFA in PBS 
and post-fixed with 0.2% crystal violet in 20% methanol. 
Cells on the upper side of the filters were carefully removed 
with cotton swabs, and the migratory cells on the lower 
side of the filter were photographed on a Zeiss Axiovert A1 
microscope and counted by ImageJ software. Five random 
fields were evaluated in each well.
Statistical analysis
Data were analyzed with GraphPad Prism software 
v5.0 (GraphPad Software, Inc., San Diego, CA, USA). 
Student’s t-test was performed to evaluate differences between 
two groups. Differences between three or more groups were 
assessed by analysis of variance (One-way or Two-way), 
followed by multiple comparisons tests. Differences were 
considered statistically significant when p ≤ 0.05.
Abbreviations
CAFs, cancer associated fibroblasts; IHC, 
immunohistochemistry; NTA, nanoparticle tracking 
analysis; PFA, paraformaldehyde; SEM, scanning electron 
microscopy; TEM, Transmission electron microscopy.
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